Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome
Trial ID or NCT#
NCT02243579
Status
NOT RECRUITING
Purpose
This phase II trial studies how well pembrolizumab works in treating patients with stage IB-IVB mycosis fungoides or Sezary syndrome that has returned after a period of improvement or has not responded to at least one type of treatment. Monoclonal antibodies, such as pembrolizumab, may block cancer growth in different ways by targeting certain cells.
Official Title
A Phase 2 Study of MK-3475 for the Treatment of Relapsed/Refractory Mycosis Fungoides/Sezary Syndrome
Investigator(s)
Michael Khodadoust
Lymphoma specialist,
Cutaneous oncology specialist,
Hematologist,
Hematologist-Oncologist
Assistant Professor of Medicine (Oncology) and of Dermatology
Youn H Kim
Dermatologic oncologist,
Cutaneous oncology specialist,
Dermatologist
The Joanne and Peter Haas, Jr., Professor for Cutaneous Lymphoma Research and Professor, by courtesy, of Medicine (Oncology)
Contact us to find out if this trial is right for you.
Contact
CCTO
650-498-7061
View on ClinicalTrials.gov
